The result: Reduced appetite You feel genuinely satisfied with less food, not deprived Fewer cravings The constant mental chatter about food quiets down Slower digestion Food stays in your stomach longer, keeping you full between meals Better blood sugar control Fewer energy crashes and hunger spikes throughout the day Cardiovascular benefits Research shows reduced risk of heart attacks and strokes in people taking GLP-1 medications This isnt willpower in a syringe
First of all, we have about 10years experience in this field, we already have a mature quality control procedure
I cant fault the concept, and if a new distiller can make rums this decent, and improve a little bit every year, you can just imagine what theyll be putting out the door within the decade
Book your aesthetic evaluation here
Novo Nordisk and the Next Wave of Weight Loss Drugs The Two-Company Market: Q1 2026 Head to Head Key Numbers Total Revenue: $19.8B (+56% YoY) Adjusted EPS: $8.55 (+156%) Mounjaro: $8.66B (+100%+ YoY) Zepbound: $4.16B (+80% YoY) US Market Share: 60.1% 2026 Guide: $82-85B (raised $2B) Total Revenue: $10.8B (beat estimates) Adjusted EPS: $1.03 (beat) Wegovy: DKK 18.2B (+12% YoY) Wegovy Pill: $354M (doubled estimates) US Market Share: 39.4% 2026 Guide: Adjusted sales decline 4-12% at CER The GLP-1 market in 2026 is a two-company duopoly with a widening gap
Alex Read more about